# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

#### FORM 8-K

# CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 15, 2016

## PHARMATHENE, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-32587	20-2726770		
(S	tate or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)		
	One Park Place, Suite 450				
	Annapolis, Maryland		21401		
(Address of principal executive offices)			(Zip Code)		
Registrant's telephone number including area code: (410) 269-2600  (Former name or former address, if changed since last report)  Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:					
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)				
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)				
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))				
	Pre-commencement communications pursuant	to Rule 13e-4(c) under the Exchange Act (17 CF	FR 240.13e-4(c))		

Item 5.02 Departure of Directors or Certain Officers	Election of Directors; Appointment of Certain	officers; Compensatory Arrangements of
Certain Officers.		

On February 15, 2016, in accordance with the recommendation of the Compensation Committee of the Board of Directors of PharmAthene, Inc. (the "Company"), the Board of Directors approved the award of a \$125,000 bonus to John Gill, the Company's President and Chief Executive Officer, based upon its conclusion that Mr. Gill had satisfied 100% of his performance objectives for a 2015 bonus.

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## PHARMATHENE, INC.

By: /s/ Philip MacNeill

Name: Philip MacNeill

Title: Vice President, Chief Financial Officer, Treasurer and Secretary

Dated: February 19, 2016